BCM
AGN

BlueCrest Capital Management’s Allergan plc AGN Stock Holding History

BlueCrest Capital Management’s Portfolio AGN Stock Details AGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-9,000
Closed -$2.32M – 805
2014
Q4 		$2.32M Buy
+9,000
New +$2.25M 0.07% 256

Other funds holding AGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
LP
Longview Partners St Peter Port, Guernsey $7.06B AUM 3.43% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BlueCrest Capital Management's AGN Position: Q4 2019 in Review

BlueCrest Capital Management sold out of Allergan plc (AGN) in Q4 2019, closing a stake of 37,594 shares — an estimated $6.33M sold.

BlueCrest Capital Management first reported a position in AGN in Q1 2015 and held it in 9 quarters. The position peaked at $12.6M in Q1 2015. 957 funds tracked by Wall St. Rank hold AGN as of Q4 2019.

  • BlueCrest Capital Management reported no remaining Allergan plc position as of Q4 2019 after selling out during the quarter.
  • BlueCrest Capital Management sold 37,594 Allergan plc shares in Q4 2019, an estimated $6.33M.
  • BlueCrest Capital Management first reported a position in Allergan plc in Q1 2015 and held it in 9 quarters.
  • BlueCrest Capital Management's Allergan plc position peaked at $12.6M in Q1 2015.
  • 957 funds tracked by Wall St. Rank held Allergan plc as of Q4 2019.

Based on BlueCrest Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.